

Supplementary Table 2. Treatments related to COVID-19 of the patients with hospital-acquired COVID-19 according to the progression to critical illness

Variable	Total (n = 204)	Non-critical illness (n = 167)	Critical illness (n = 37)	p value
Antibiotics	128 (63.1)	98 (58.7)	30 (83.3)	0.010
Vasopressor		2 (1.2) ^{a)}	23 (62.2)	< 0.001
Neuromuscular blocker			3 (8.1)	
Dexamethasone	28 (13.7)	13 (7.6)	15 (40.5)	< 0.001
Tocilizumab	3 (1.5)	3 (1.8)	0 (0)	0.947
Ritonavir-nirmatrelvir	9 (4.4)	9 (5.3)	0 (0)	0.316
Remdesivir	109 (53.4)	79 (47.3)	30 (81.1)	< 0.001
Molnupiravir	1 (0.5)	1 (0.6)	0 (0)	> 0.999
Prone position			3 (8.1)	
Inhaled nitric oxide			1 (2.7)	
Continuous renal replacement therapy			5 (13.5)	
Extracorporeal membrane oxygenation			0 (0)	
High-flow nasal cannula			20 (54.1)	
Non-invasive ventilation			1 (2.7)	
Mechanical ventilation			9 (24.3)	

Values are presented as number (%).

COVID-19, coronavirus disease 2019.

^{a)}Two non-critical patients received vasopressors: one had hypovolemic shock due to diuretic use, and the other had atrial fibrillation with a rapid ventricular response and low blood pressure that improved after cardioversion.